9 Meters Biopharma Inc
(NQ:
NMTR
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 9 Meters Biopharma Inc
< Previous
1
2
3
Next >
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
May 30, 2023
Via
ACCESSWIRE
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
May 15, 2023
Via
ACCESSWIRE
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
April 05, 2023
Via
ACCESSWIRE
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
March 28, 2023
Via
ACCESSWIRE
9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 15, 2023
Via
ACCESSWIRE
9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
March 14, 2023
Via
ACCESSWIRE
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023
Via
ACCESSWIRE
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
January 31, 2023
Via
ACCESSWIRE
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome
November 29, 2022
Via
ACCESSWIRE
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy
November 14, 2022
Via
ACCESSWIRE
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
November 08, 2022
Via
ACCESSWIRE
9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific Meeting
October 24, 2022
Via
ACCESSWIRE
9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
October 18, 2022
Via
ACCESSWIRE
9 Meters Biopharma Announces 1-for-20 Reverse Stock Split
October 17, 2022
Via
ACCESSWIRE
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome
September 26, 2022
Via
ACCESSWIRE
9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022
Via
ACCESSWIRE
9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress
September 01, 2022
Via
ACCESSWIRE
9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conference
August 31, 2022
Via
ACCESSWIRE
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
August 15, 2022
Via
ACCESSWIRE
9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
July 06, 2022
RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...
From
9 Meters Biopharma
Via
AccessWire
Exposures
Product Safety
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
June 30, 2022
Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
June 30, 2022
RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today...
From
9 Meters Biopharma
Via
AccessWire
Exposures
Product Safety
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
June 21, 2022
RALEIGH, NC / ACCESSWIRE / June 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today...
From
9 Meters Biopharma
Via
AccessWire
Exposures
Product Safety
9 Meters Biopharma to Participate in the 2022 BIO International Convention
June 13, 2022
RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
May 19, 2022
RALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis
May 18, 2022
RALEIGH, NC / ACCESSWIRE / May 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022
May 16, 2022
- On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in June - Cash balance as of March 31, 2022, of $37.2 million is expected to...
From
9 Meters Biopharma
Via
AccessWire
Exposures
Product Safety
9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
May 05, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease
April 20, 2022
RALEIGH, NC and SANTA ROSA, CA / ACCESSWIRE / April 20, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating...
From
9 Meters Biopharma
Via
AccessWire
9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions
April 13, 2022
RALEIGH, NC / ACCESSWIRE / April 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases,...
From
9 Meters Biopharma
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.